Viral Hepatitis
Copyright ©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Feb 28, 2005; 11(8): 1109-1114
Published online Feb 28, 2005. doi: 10.3748/wjg.v11.i8.1109
Table 1 Clinical features of patients.
PtAge (yr)SexTherapy drugDuration (d)1ConditionHistory of immunosuppresive or cytotoxic therapyOutcome
Patients who received early introduction of high-dose corticosteroids
1.27MMPSL/PSL1Ulcerative colitis+Death
2.36MPSL2-Re covery
3.41FPSL3-Recovery
4.27MPSL4-Recovery
5.41FPSL4Schizophrenia-Recovery
6.33MPSL+Lam4-Recovery
7.68FPSL+Lam4Non-Hodgkin’s lymphoma+Recovery
8.56MPSL5-Recovery
9.57FPSL5-Recovery
10.39MPSL5Acute lymphocytic leukemia+Recovery
11.43MPSL10-Recovery
Patients who did not receive early introduction of high-dose corticosteroids
12.49FPSL+IFN14Non-Hodgkin’s lymphoma+Death
13.59FPSL14-Death
14.47MPSL+Lam14Ulcerative colitis+Death
15.58MPSL15-Death
16.59MPSL17-Death
17.36FMPSL/PSL+IFN28Breast cancer+Death
18.68FPSL120Pemphigoid+Death
19.41Mglycyrrhizin-Recovery
20.55Mglycyrrhizin-Recovery
21.59Mglycyrrhizin-Death
22.28MglycyrrhizinMental retardation-Death
Table 2 Biochemical and histological features of patients at admission.
PtPT(%)ALT(IU/L)T-bili(mg/dL)HBeAg/HBeAbIgM-HBc(cut-off index)HBV DNApolymerase (cpm)HBV DNA(Meq/mL)Liver histology
Patients who received early introduction of high-dose corticosteroids
1.1616989.5-/+2.610NDND
23126893+/-0.33517NDND
35747415.2-/+0.250<0.70ND
43749512.0+/-0.3999920 pg/mLCAH (F2, severe)
5371558-/-0.5ND1+ND
65620804.2+/+1.8595<0.70CAH (F2, severe)
7571673.1-/+ND6425NDND
8.3722573.7-/+2.32820CAH (F3, severe)
9342247.3+/-1.4251.2ND
10563993.8-/+3.711600NDSubmassive necrosis
11461016.4-/+0.310<0.70LC, submassive necrosis
Patients who did not receive early introduction of high-dose corticosteroids
122925412.6-/+1.10<0.70ND
13.342 64319.3+/-1.60<0.70ND
14.322402.9-/+0.5127353800ND
152822813.3-/+3.3161.1Submassive necrosis
16.2915013.3-/+0.253856>10000Submassive necrosis
171954911.1+/-7.621.9LC, submassive necrosis
18289546.3-/+NDNDNDSubmassive necrosis
19.5921412.9+/+0.45NDCAH (F3, moderate)
203836207.7-/+0.20<0.70CAH (F3, moderate)
21.331648.9+/-ND7576NDLC, submassive necrosis
22.21498.0+/-1.00<0.70Submassive necrosis